Benzinga | Jul 22, 2021 08:12AM EDT

BioVie To Present Rationale For Use Of NE3107 For Treatment Of Alzheimer's Disease At 2021 Alzheimer's Association International Conference

BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that Poster 55458 entitled "Rationale for an Anti-inflammatory Insulin Sensitizer in a Phase 3 Alzheimer's Disease Trial" by Christopher L Reading, PhD, BioVie's Executive Vice President for Neuroscience Research & Development will be presented at the 2021 Alzheimer's Association International Conference (AAIC), July 28, 2021.